Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-252 in Parkinson's Disease with Motor Fluctuations
NCT07422675Phase 1Recruiting
- Sponsor
- Serina Therapeutics, Inc.
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Polymer-based Nanoparticles, Transdermal Patches, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised trial of SER-252 in Parkinson's disease (PD) (2 arms), sponsored by Serina Therapeutics, Inc. Primary endpoints: Incidence and Temporal Profile of Treatment-Emergent Adverse Events at Day 21, Incidence of Moderate or Severe TEAEs Related to Study Intervention at Day 21 and 12 more. Started Feb 2026; status: recruiting.
02
Drugs
SER-252
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07422675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422675.